比克替拉韦在真实世界HIV感染者中的群体药代动力学
研究基于瑞士洛桑大学医院2019年7月至2024年7月的治疗药物监测数据,纳入572名HIV感染者的708份稳态血药浓度,建立比克替拉韦群体药代动力学模型。采用一室模型加一阶吸收和消除,发现年龄和体重显著影响清除率,但变化幅度不具临床意义。结论认为常规治疗药物监测价值有限,但在怀疑耐药、依从性差、肥胖、妊娠或药物相互作用时可考虑。
要点
- 比克替拉韦群体药代动力学可用一室模型加一阶吸收和消除描述。
- 年龄和体重影响清除率,但变化幅度不具临床意义。
- 常规治疗药物监测价值有限,特殊情形可考虑。
核心结论
- 比克替拉韦常规治疗药物监测价值有限,但在怀疑病毒耐药、依从性差、肥胖、妊娠或监测药物相互作用时可考虑。
研究设计与样本
- 研究纳入瑞士洛桑大学医院2019年7月至2024年7月接受治疗药物监测的572名HIV感染者,共708份稳态血浆浓度,采用非线性混合效应方法(Monolix®)建立群体药代动力学模型。
主要发现
- 一室模型加一阶吸收和消除最佳描述比克替拉韦药代动力学。
- 年龄和体重显著影响比克替拉韦清除率:51岁、100 kg者较51岁、70 kg者清除率增加13%;80岁、70 kg者较51岁、70 kg者降低11%。
- 上述影响不具临床意义,不需临床干预。
临床怎么用
- 不推荐对比克替拉韦进行常规治疗药物监测。
- 怀疑病毒耐药或依从性差时可考虑治疗药物监测。
- 肥胖个体、孕妇或需监测药物相互作用时可考虑治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir population PK in people with HIV (PWH) and to identify covariates affecting its disposition. METHODS: Bictegravir concentrations were obtained from PWH as part of a therapeutic drug monitoring (TDM) follow-up performed at the Lausanne University Hospital, Switzerland, between July 2019 and July 2024. Demographic data, clinical data and co-medications were recorded during the routine Swiss HIV Cohort Study (SHCS) visits. A population PK model was developed using a non-linear mixed-effect approach with Monolix®. RESULTS: A total of 708 steady-state plasma concentrations from 572 PWH were available for the analysis. A one-compartment model with first-order absorption and elimination best characterized bictegravir PK. Age and body weight were found to significantly affect bictegravir clearance, individuals of 51 years weighing 100 kg showing a 13% increase, and those aged 80 years weighing 70 kg a 11% decrease, relative to an individual weighing 70 kg and aged 51 years. These effects are not deemed clinically significant and do not warrant a clinical intervention. CONCLUSIONS: Considering the good safety and efficacy profile of bictegravir, routine TDM is of limited value for bictegravir. However, TDM of bictegravir could be beneficial in case of suspected viral resistance or non-adherence, in special subpopulations (i.e. obese individuals and pregnant women), or to monitor drug-drug interactions.
引用
- Ekobena P, Briki M, Dao K, et al. Population pharmacokinetics of bictegravir in real-world people with HIV. J Antimicrob Chemother. 2025. PMID: 40798866. doi:10.1093/jac/dkaf297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。